Literature DB >> 7789328

The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein.

K Ogino1, D Burkhoff, J P Bilezikian.   

Abstract

PTH and PTH-related protein (PTHrP) have been regarded to have positive inotropic effects on the heart as well as positive chronotropic and vasodilator effects. However, inotropy due to a direct effect of these peptides has not heretofore been distinguished from an indirect inotropic effect as a result of altered heart rate or coronary flow. The aim of this study was to determine whether PTH and PTHrP have direct inotropic effects in isolated perfused rat hearts. Three groups of hearts were studied; in all groups, hearts contracted isovolumically and were perfused with a constant coronary pressure. In the control group, heart rate, coronary flow, peak pressure (LVPmax), peak rate of rise of LV pressure (dP/dtmax), and peak intracellular calcium (measured by aequorin) all increased with PTH and PTHrP in a dose-dependent manner. When heart rate was fixed by pacing in a second group of rats, PTH and PTHrP increased coronary flow, LVPmax, and dP/dtmax significantly, indicating that inotropic actions were not mediated solely by chronotropic effects. However, when heart rate was fixed by pacing and, additionally, coronary flow was held constant (by maximal prevasodilation with nitroprusside) in a third group of rats, there was no significant effect of either PTH or PTHrP on LVPmax, dP/dtmax, or peak intracellular calcium. To demonstrate the responsiveness of this latter preparation to inotropic stimulation, the beta-adrenergic agonist, isoproterenol, increased LVPmax, dP/dtmax, and peak calcium even when heart rate was fixed and vasodilation was maximal. Thus, PTH and PTHrP are inotropic agents by virtue of their influence on coronary flow and heart rate, but not by any direct effect on contractile elements in the heart.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789328     DOI: 10.1210/endo.136.7.7789328

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Adolfo Garcia-Ocaña; Alessandro Bisello; Bruce W Hollis; Caren Gundberg; Andrew F Stewart
Journal:  Osteoporos Int       Date:  2005-09-07       Impact factor: 4.507

2.  The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism.

Authors:  Kristin Godang; Karolina Lundstam; Charlotte Mollerup; Stine Lyngvi Fougner; Ylva Pernow; Jörgen Nordenström; Thord Rosen; Svante Jansson; Mikael Hellström; Jens Bollerslev; Ansgar Heck
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

3.  Elevation of parathyroid hormone levels in atrial fibrillation.

Authors:  Michiel Rienstra; Steven A Lubitz; Michael L Zhang; Rebecca R Cooper; Patrick T Ellinor
Journal:  J Am Coll Cardiol       Date:  2011-06-21       Impact factor: 24.094

4.  Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure.

Authors:  D Gruson; T Lepoutre; S A Ahn; J M Ketelslegers; M F Rousseau
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

5.  Predicting hospital cost in CKD patients through blood chemistry values.

Authors:  Russell W Bessette; Randy L Carter
Journal:  BMC Nephrol       Date:  2011-12-01       Impact factor: 2.388

6.  Carotid artery plaque thickness is associated with increased serum calcium levels: the Northern Manhattan study.

Authors:  Mishaela R Rubin; Tanja Rundek; Donald J McMahon; Hye-Seung Lee; Ralph L Sacco; Shonni J Silverberg
Journal:  Atherosclerosis       Date:  2006-10-09       Impact factor: 5.162

7.  Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone.

Authors:  Y Furuse; K Ogino; M Shimoyama; N Sasaki; I Hisatome
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

8.  Cardiac structure and diastolic function in mild primary hyperparathyroidism.

Authors:  M D Walker; J B Fleischer; M R Di Tullio; S Homma; T Rundek; E M Stein; C Zhang; T Taggart; D J McMahon; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

Review 9.  Cardiovascular aspects of primary hyperparathyroidism.

Authors:  M D Walker; S J Silverberg
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 10.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.